NCT06761703Completed
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
Community Outreach Support and Engagement Using Online Strategies - Decentralized Insights Into Therapy Adoption and Value
Source: ClinicalTrials.gov · Last updated 14 Jan 2025
Brief summary (registry, in English)
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 1 Jan 2025
- Start date
- 14 Nov 2024
- Primary completion date
- 6 Jan 2025
- Lead sponsor
- Amgen
- Diseases
- Obesity
- NCT number
- NCT06761703
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 14 Nov 2024 to the primary completion date, 6 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving treatment in another investigational device or drug study, or participation in a current clinical trial.
Other illness
- Self-reported sensitivity/allergy to any of the components of the self-draw collection device including stainless steel or elements commonly found in stainless steel.
- Self-reported circulatory conditions causing difficulty in drawing capillary blood.
- Known history of bleeding diathesis or any coagulation disorder.
- History of skin disorders, abnormal skin integrity or atypical skin health within the areas to be tested in the upper arm.
Other
- Self-reported fear of blood.
Who the study is looking for
- Adults 18 - 80 years of age.
- Living in the United States.
- Consented from the Inspire online platform patient community for COSMOS-DIGITAL.
- Self-Reported current use of, and intention to continue for at least 30 days, one of the following medications for the indications of weight management/obesity:
- Semaglutide (wegovy)
- Tirzepatide (zepbound)
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| YourBio Health/CRT Coordinator of this site? Confirm its status | Medford | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.